Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.26 -1.6%	$1.27	$1.05 ▼ $10.16	$39.51M	1.65	280,616 shs	140,802 shs
AIMD Ainos	$2.46 -5.4%	$2.86	$2.00 ▼ $5.00	$10.31M	2.2	75,391 shs	33,129 shs
ATHE Alterity Therapeutics	$5.01 -1.0%	$4.57	$1.00 ▼ $7.00	$44.42M	0.66	205,931 shs	45,942 shs
CGTX Cognition Therapeutics	$0.67 +13.9%	$0.45	$0.22 ▼ $1.29	$41.37M	0.99	19.44 million shs	4.06 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	-11.89%	-2.70%	-10.64%	-84.96%
AIMD Ainos	0.00%	-4.65%	-25.23%	-8.89%	-24.89%
ATHE Alterity Therapeutics	0.00%	-23.51%	+24.16%	+46.28%	+213.14%
CGTX Cognition Therapeutics	0.00%	-20.55%	+47.00%	+49.71%	-33.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.7867 of 5 stars	3.5	5.0	0.0	2.5	0.6
AIMD Ainos	0.8833 of 5 stars	0.0	5.0	0.0	1.7	0.6
ATHE Alterity Therapeutics	1.7605 of 5 stars	3.3	3.0	1.1	1.7	0.0
CGTX Cognition Therapeutics	2.3932 of 5 stars	3.6	2.0	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,305.90% Upside
AIMD Ainos	0.00	N/A	N/A	N/A
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	139.52% Upside
CGTX Cognition Therapeutics	3.25	Buy	$2.83	324.53% Upside

Current Analyst Ratings Breakdown

Latest AIMD, ACRV, ATHE, and CGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
AIMD Ainos	$20K	515.37	N/A	N/A	$5.51 per share	0.45
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.22	N/A	N/A	N/A	N/A	-44.66%	-40.94%	8/12/2025 (Estimated)
AIMD Ainos	-$14.86M	-$6.45	N/A	∞	N/A	N/A	-88.07%	-48.60%	8/4/2025 (Estimated)
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
CGTX Cognition Therapeutics	-$33.97M	-$0.74	N/A	N/A	N/A	N/A	-194.42%	-115.14%	8/6/2025 (Estimated)

Latest AIMD, ACRV, ATHE, and CGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.11	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/12/2025	Q1 2025	AIMD Ainos	N/A	-$1.05	N/A	-$0.21	N/A	$0.11 million
5/6/2025	Q1 2025	CGTX Cognition Therapeutics	-$0.12	-$0.14	-$0.02	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	11.17	11.17
AIMD Ainos	0.84	2.00	1.91
ATHE Alterity Therapeutics	N/A	3.84	N/A
CGTX Cognition Therapeutics	N/A	2.09	2.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
AIMD Ainos	N/A
ATHE Alterity Therapeutics	2.14%
CGTX Cognition Therapeutics	43.35%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
AIMD Ainos	10.39%
ATHE Alterity Therapeutics	38.80%
CGTX Cognition Therapeutics	14.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.35 million	27.62 million	Not Optionable
AIMD Ainos	40	4.19 million	3.76 million	Not Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
CGTX Cognition Therapeutics	20	61.99 million	53.07 million	Not Optionable

AIMD, ACRV, ATHE, and CGTX Headlines

Recent News About These Companies

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

July 30, 2025 | finance.yahoo.com

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

July 29, 2025 | globenewswire.com

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

July 21, 2025 | globenewswire.com

Cognition Therapeutics stock soars after DLB study results

July 16, 2025 | in.investing.com

Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies

July 16, 2025 | quiverquant.comQ

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

July 16, 2025 | globenewswire.com

Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress

July 11, 2025 | insidermonkey.com

Cognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

July 11, 2025 | finanznachrichten.de

Cognition Therapeutics Shares Jump 75% After FDA Discussion on Alzheimer’s Treatment

July 11, 2025 | msn.com

Cognition soars 35% after positive FDA meeting on Alzheimer's asset zervimesine

July 11, 2025 | msn.com

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease

July 10, 2025 | finance.yahoo.com

Cognition Therapeutics stock soars after FDA meeting on Alzheimer’s drug

July 10, 2025 | in.investing.com

Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA

July 10, 2025 | quiverquant.comQ

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

July 10, 2025 | globenewswire.com

Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data

July 5, 2025 | benzinga.com

CGTX - Cognition Therapeutics Inc Executives - Morningstar

July 3, 2025 | morningstar.comM

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target

July 1, 2025 | finance.yahoo.com

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

July 1, 2025 | globenewswire.com

Cognition Therapeutics, Inc. (CGTX) - Yahoo Finance

June 30, 2025 | finance.yahoo.com

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

June 25, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
How a Government Loan Changes the Game for Plug Power
By Jeffrey Neal Johnson | July 4, 2025
View How a Government Loan Changes the Game for Plug Power
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?
By Sam Quirke | July 29, 2025
View Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag?

AIMD, ACRV, ATHE, and CGTX Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.26 -0.02 (-1.56%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.26 0.00 (0.00%)

As of 08/1/2025 07:46 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Ainos NASDAQ:AIMD

$2.46 -0.14 (-5.38%)

As of 08/1/2025 03:59 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Alterity Therapeutics NASDAQ:ATHE

$5.01 -0.05 (-0.99%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.99 -0.02 (-0.50%)

As of 08/1/2025 07:00 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Cognition Therapeutics NASDAQ:CGTX

$0.67 +0.08 (+13.93%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.01 (+1.44%)

As of 08/1/2025 07:59 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time